The Pharma Data

JANUARY 19, 2021

are acting as joint book-running managers for the offering. Syros is redefining the power of small molecules to control the expression of genes. Syros has also granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock offered in the public offering on the same terms and conditions.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

The Pharma Data

DECEMBER 9, 2020

is acting as the sole book-running manager for the offering. The clinical pipeline also includes , an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Treatment 52

Vial

FEBRUARY 19, 2024

We can link small molecule drugs to a payload that would enter in the cell and kill it. We have the capability of different types of targets, whether small molecules or antibodies. I don’t know if you’ve read that book, but it’s a very important book, where you always do your best.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

To Boehringer’s first and most significant argument, that Congress intended the terms “strength” to match FDA’s interpretation in 2009—prior to the codification of the definition in 21 C.F.R. FDA replied that its definition of strength including concentration was clear even in 2009.

FDA 59

FDA Biosimilars Production Regulations 59

The Pharma Data

JANUARY 19, 2021

and Credit Suisse are acting as joint book-running managers for the offering. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia, into Phase 1 clinical development. SVB Leerink, Piper Sandler & Co.

Small Molecule 40

Small Molecule Clinical Development Treatment Disease 40

The Pharma Data

NOVEMBER 12, 2020

are acting as joint book-running managers for the offering. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co.

Clinical Trials 40

Clinical Trials Small Molecule Treatment Production 40

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. Our long-time clinical development lead, Bhaskar Srivastava, an M.D.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

Codon

FEBRUARY 28, 2023

The graphic is from Ron Milo and Rob Phillips ’ book, Cell Biology by the Numbers , but the calculations originally appeared in the textbook, “ Physiology of the Bacterial Cell.” A single ribosome could translate the first Harry Potter book in two-and-a-half hours while making about three dozen typos along the way.

RNA 52

RNA DNA Cell Biology Small Molecule 52

Agency IQ

OCTOBER 6, 2023

There were 21 NMEs added to the FDA’s Purple Book , which provides information about all biological products licensed by the FDA. For example, these products face a much more arduous path for development of biosimilar or interchangeable products than that of generics for small molecules.

FDA 52

FDA Biosimilars Science Drugs 52

PLOS: DNA Science

JUNE 22, 2023

The candidate drug, vorasidenib, is a small molecule that inhibits survivin. Gleevec came from a massive effort throughout the 1980s to screen more than 400 small molecules for one that would block the activity of the errant tyrosine kinase, without derailing other important enzymes. It is a cyclin-dependent kinase.

Drugs 52

Drugs Small Molecule DNA Clinical Trials 52

KIF1A

AUGUST 20, 2024

” And while the Rosens have been open books when asked about their experiences, we’ve also always cautioned that the study is still underway. The effects of an ASO administered to the eye have yet to be determined, and we are also investigating small-molecule therapies to treat this high-priority symptom.

Science 52

Science Treatment Therapies Small Molecule 52

Codon

APRIL 30, 2023

Read An automated platform to make riboswitches (RNA strands that bind to small molecules and then quickly switch their structure) that can sense specific proteins. Read When I was a kid, one of my favorite books was about Balto, the sled dog that ran hundreds of miles to deliver diphtheria antitoxin to Nome, Alaska in 1925.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Read An automated platform to make riboswitches (RNA strands that bind to small molecules and then quickly switch their structure) that can sense specific proteins. Read When I was a kid, one of my favorite books was about Balto, the sled dog that ran hundreds of miles to deliver diphtheria antitoxin to Nome, Alaska in 1925.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

APRIL 7, 2023

About BRAFTOVI + MEKTOVI BRAFTOVI is an oral small molecule BRAF kinase inhibitor and MEKTOVI is an oral small molecule MEK inhibitor which target key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Am Soc Clin Oncol Educ Book. Updated November 17, 2022. Accessed February 2, 2023. 2019;39:207-215.

FDA 40

FDA FDA Approval Small Molecule Drugs 40

Codon

APRIL 16, 2023

I put out a call on Twitter for book recommendations, and want to share them with you here. Read Aer Therapeutics, a University of California, San Francisco lab spinout developing an inhaled small molecule drug for chronic obstructive pulmonary disease, raised $36 million in a Series A. million ($1.58

Engineering 52

Engineering DNA RNA Science 52

Codon

MAY 30, 2023

Read Programming inactive RNA-binding small molecules into bioactive degraders. Molecular Therapy. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Nature Communications. Read Synthetic biology pathway to nucleoside triphosphates for expanded genetic alphabets. ACS Synthetic Biology.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

Read Programming inactive RNA-binding small molecules into bioactive degraders. Molecular Therapy. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Nature Communications. Read Synthetic biology pathway to nucleoside triphosphates for expanded genetic alphabets. ACS Synthetic Biology.

DNA 52

DNA RNA Engineering Vaccine 52